Unleash Immuno Oncolytics

Based in the US, Unleash Immuno Oncolytics develops innovative armed oncolytic viruses targeting malignant cancer cells, enhancing the immune response against tumors. Founded in 2015, Unleash Immuno Oncolytics is dedicated to pioneering oncolytic virotherapy solutions. The firm is based in Missouri City, US. The company has engaged in one funding deal, receiving an investment of JPY 36.

96 mn from Oncolys BioPharma Inc. in February 2018, which enabled expansion of its operations. Daniel Katzman serves as both the CEO and founder. Unleash Immuno Oncolytics specializes in the development of innovative armed oncolytic viruses, particularly their flagship product, UIO-524.

This product is engineered to target malignant cancer cells and the surrounding tumor-associated stroma, promoting comprehensive infection throughout the tumor mass. UIO-524 utilizes a proprietary mechanism that enhances replication in tumor microenvironments characterized by inflammation and hypoxia, aiming to disrupt tumor architecture and modify the tumor microenvironment, thereby activating the immune system to eliminate cancer cells. The company primarily focuses on serving the oncology markets in North America and Europe, tackling metastatic diseases with a novel therapeutic approach that integrates multiple mechanisms of action in one treatment. Unleash Immuno Oncolytics generates revenue mainly through partnerships and collaborations within the biopharmaceutical sector.

Their business model revolves around the commercialization of UIO-524 and potential subsequent products developed from their proprietary oncolytic virotherapy technology. The firm collaborates with healthcare institutions, oncology clinics, and pharmaceutical companies to ensure the effective distribution and application of their therapies, likely establishing pricing structures based on the unique attributes of their offerings, which hold significant value in advanced cancer treatment. Unleash Immuno Oncolytics plans to utilize the recent investment of JPY 36. 96 mn from Oncolys BioPharma Inc.

to support its growth strategy. This funding will enhance their capabilities in developing and launching new products, specifically in advancing the UIO-524 and exploring additional therapeutic options. The company is targeting expansion into new geographical markets, particularly in Europe and Asia, by 2025, to broaden its reach in the oncology sector. The acquisition in February 2018 is expected to facilitate this growth trajectory.